What is the Radioligand Therapy Market Size in 2026?

The global radioligand therapy market was valued at USD 3.20 billion in 2025 and is projected to grow from USD 4.08 billion in 2026 to approximately USD 36.47 billion by 2035, expanding at a CAGR of 27.55% from 2026 to 2035. The market is experiencing rapid growth due to increasing cancer awareness, continuous innovation in radioligand therapies, and supportive regulatory frameworks worldwide.

Radioligand therapy is emerging as a highly targeted oncology treatment approach that delivers radiation directly to cancer cells, improving treatment precision while minimizing damage to surrounding healthy tissues.

Read Also: Transformational Skincare Market

Radioligand Therapy Market Key Takeaways

• North America dominated the market with 82% share in 2025.

• Asia Pacific is expected to grow at the fastest rate during the forecast period.

• By product, Lutetium Lu 177 Vipivotide Tetraxetan led the market in 2025.

• Lutetium Lu 177 Dotatate is projected to grow at the highest CAGR.

• By indication, the prostate cancer segment dominated the market in 2025.

• The neuroendocrine tumors segment is expected to grow rapidly in the coming years.

• By target, the prostate-specific membrane antigen (PSMA) segment led the market.

• The somatostatin receptor segment is expected to witness significant growth.

• By end user, tertiary care academic/comprehensive cancer centers held the largest share.

Radioligand Therapy Market Overview

Radioligand therapy is an advanced targeted cancer treatment that combines a radioactive isotope with a tumor-targeting molecule. This molecule binds specifically to cancer cells and delivers radiation directly to the tumor.

Two main types of isotopes are used:

• Alpha-emitting isotopes: Deliver high-energy radiation over a very short distance for precise tumor destruction.

• Beta-emitting isotopes: Travel slightly farther and treat a broader tumor region.

This targeted radiation approach significantly reduces damage to surrounding healthy tissues compared to conventional therapies like chemotherapy.

The regulatory landscape is also evolving, with global health authorities increasingly supporting the clinical adoption of radioligand therapies in oncology treatment protocols.

Impact of Artificial Intelligence on the Radioligand Therapy Market

Artificial intelligence (AI) is playing an important role in advancing radioligand therapy research and clinical applications.

AI technologies support:

• Advanced ligand design and development

• Improved imaging in preclinical research

• Data-driven treatment planning

• Predictive patient selection

AI-driven digital twin models help simulate treatment outcomes and shorten drug development timelines, reducing costs during preclinical phases.

Additionally, AI-based imaging technologies help improve diagnostic accuracy in nuclear medicine imaging techniques such as:

• SPECT scans

• PET scans

Advanced AI architectures such as convolutional neural networks help enhance low-count imaging quality and improve decision-making during cancer treatment planning.

AI is also helping automate radiopharmaceutical production and quality control, enabling faster availability of radioligand therapies in oncology care.

Radioligand Therapy Market Trends

Rising Cancer Awareness

Growing awareness among clinicians and patients is accelerating early cancer diagnosis and driving the adoption of targeted therapies such as radioligand treatments.

Expansion of Nuclear Medicine Infrastructure

Government initiatives aimed at expanding specialized cancer centers and nuclear medicine facilities are improving access to radioligand therapy treatments worldwide.

Adoption of Alpha and Beta Isotopes

The growing use of alpha- and beta-emitting isotopes is enabling precise tumor cell destruction while expanding applications in oncology treatments.

Manufacturing Expansion by Key Players

Leading pharmaceutical companies are scaling manufacturing capacities to strengthen the global radioligand supply chain and support the growth of precision oncology.

Segment Insights

Product Insights

Lutetium Lu 177 Vipivotide Tetraxetan Dominated the Market

The Lutetium Lu 177 Vipivotide Tetraxetan segment accounted for the largest share of the market in 2025.

This therapy is marketed under the brand Pluvicto, developed by Novartis through its subsidiary Advanced Accelerator Applications.

It is designed to treat prostate-specific membrane antigen (PSMA)-expressing metastatic prostate cancer in patients who have already received hormone therapy.

The therapy works by delivering ionizing radiation directly to tumor cells, helping delay chemotherapy in eligible patients.

However, potential risks associated with the treatment include:

• Radiation exposure

• Myelosuppression

• Renal toxicity

Lutetium Lu 177 Dotatate to Grow at the Fastest Rate

The Lutetium Lu 177 Dotatate segment is expected to register the fastest growth rate due to its effectiveness in treating neuroendocrine tumors.

This therapy is marketed under the brand Lutathera and is widely used for treating somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The rising global incidence of cancer and increasing demand for targeted radiotherapy solutions are supporting the segment’s rapid growth.

Indication Insights

Prostate Cancer Dominated the Market

The prostate cancer segment held the largest share in 2025 due to the increasing number of prostate cancer diagnoses worldwide.

Prostate cancer remains one of the most common cancers among men and is a major contributor to cancer-related deaths.

In many cases, the disease progresses slowly and may initially require active surveillance. However, targeted treatments such as radioligand therapy are becoming essential for advanced disease management.

Neuroendocrine Tumors to Grow Rapidly

The neuroendocrine tumors (NETs) segment is expected to grow at the fastest CAGR during the forecast period.

NETs are rare tumors that may develop in various organs, including:

• Lungs

• Pancreas

• Small intestine

• Appendix

• Rectum

Increasing diagnosis and improved treatment approaches using targeted radioligand therapies are supporting strong segment growth.

Target Insights

Prostate-Specific Membrane Antigen (PSMA) Led the Market

The prostate-specific membrane antigen (PSMA) segment dominated the market due to the growing adoption of PSMA PET diagnostic imaging.

PSMA is considered a highly validated target for both diagnostic imaging and therapeutic applications in prostate cancer.

Advances in early cancer detection and treatment technologies are supporting continued growth in this segment.

Somatostatin Receptor Segment to Grow Rapidly

The somatostatin receptor segment is expected to grow significantly as these receptors are highly expressed in neuroendocrine tumors.

Radioligand therapies such as Lutetium-177 DOTATATE bind to these receptors and deliver radiation directly to tumor cells while sparing healthy tissues.

Growing clinical evidence showing improved patient survival rates is accelerating the adoption of these targeted therapies.

End User Insights

Tertiary Care Academic and Comprehensive Cancer Centers Dominated

The tertiary care academic and comprehensive cancer centers segment led the market in 2025.

These centers possess:

• Advanced oncology infrastructure

• Highly specialized medical professionals

• Research-driven treatment programs

• High patient volumes

They also play a major role in clinical trials and early adoption of innovative cancer therapies.

Specialized Nuclear Medicine Centers to Grow Rapidly

The specialized nuclear medicine centers segment is expected to grow at the fastest rate.

These facilities focus specifically on:

• Nuclear imaging

• Radiopharmaceutical therapies

• Precision oncology treatments

Their specialized expertise and advanced equipment enable highly efficient radioligand therapy procedures.

Regional Insights

North America Radioligand Therapy Market

North America dominated the global market in 2025.

• Market size 2025: USD 2.62 billion

• Projected market size 2035: USD 30.09 billion

• CAGR: 27.65%

The region benefits from:

• Advanced cancer treatment infrastructure

• High adoption of PET diagnostic technologies

• Well-established reimbursement systems

• Strong presence of theranostic centers

United States Radioligand Therapy Market

The United States plays a key role in the global radioligand therapy market.

• Market size 2025: USD 2.10 billion

• Projected market size 2035: USD 24.22 billion

• CAGR: 27.70%

High prostate cancer incidence and strong radiopharmaceutical innovation are major drivers of market growth.

Asia Pacific Radioligand Therapy Market

Asia Pacific is expected to witness the fastest growth during the forecast period due to:

• Rising cancer prevalence

• Increasing healthcare investments

• Expansion of nuclear medicine infrastructure

• Growing adoption of advanced oncology treatments

Countries such as China, Japan, and India are emerging as major markets in the region.

Government initiatives supporting advanced cancer treatment facilities are further strengthening regional growth.

Leading Companies in the Radioligand Therapy Market

Key companies operating in the global market include:

• Novartis

• Bayer

• Eli Lilly and Company

• AstraZeneca

• Bristol Myers Squibb

• Telix Pharmaceuticals

• Clarity Pharmaceuticals

• Radiopharm Theranostics

• ITM Isotope Technologies Munich

For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com